DDP-induced cytotoxicity is net influenced by p53 in nine human ovarian cancer cell lines with different p53 status

British Journal of Cancer

Volumn 76, Issue 4, 1997, Pages 474-479

  De Feudis, P ^a   Debernardis, D ^b   Beccaglia, P ^a   Valenti, M ^b   Graniela Sire E ^a   Arzani, D ^b   Stanzione, S ^b   Parodi, S ^b   D'Incalci, M ^a   Russo, P ^b   Broggini, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Apoptosis; Cisplatin; Ovarian cancer; p53

Indexed keywords

CISPLATIN; MESSENGER RNA; MUTANT PROTEIN; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE INDUCTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 8544262181     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.412     Document Type: Article

References (30)

1. Akashi M, Hachiya M, Osawa Y, Spirin K, Suzuki G and Koeffler HP (1995) Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J Biol Chem 270: 19181-19187
2. Bertrand R, Kohn KW, Solary E and Pommier Y (1995) Detection of apoptosis-associated DNA fragmentation using a rapid quantitative filter elution assay. Drug Dev Res 34: 138-144
3. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B and Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684
4. Cannistra SA (1993) Cancer of the ovary. N Engl J Med 329: 1550-1559
5. Damia G, Imperatori L, Stefanini M and D'Incalci M (1996) Sensitivity of CHO mutants cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 66: 779-783
6. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F (1992) Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808
7. Debernardis D, Graniela Siré E, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M and Broggini M (1997) P53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57: 870-874
8. Eastman A (1983) Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum (II) and cis-dichloro(ethylenediamine)platinum. Biochemistry 22: 3927-3933
9. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJJ and O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654
10. Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H and Hopkins PJ (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14: 275-285
11. Graniela Siré EA, Vikhanskaya F and Broggini M (1995) Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann Oncol 6: 589-593
12. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
13. Hoeijmakers JH (1993) Nucleotide excision repair. II. From yeast to mammals. Trends Gene 19: 211-217
14. Hoeijmakers JHJ (1994) Human nucleotide excision repair syndromes: molecular clues to unexpected intricacies. Eur J Cancer 30A: 1912-1921
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
16. Lane DP (1992) Cancer. p53, guardian of the genome [news; comment]. Nature 358: 15-16
17. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395
18. Nih (1994) Ovarian cancer: screening, treatment and followup. NIH Consensus Statement 12 (3): 1-30
19. Ozols RF and Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 18: 222-232
20. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562
21. Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, Tsujimoto H, Imanishi T, Ohgaki M, Ohyama T, Yamazaki J, Hagiwara A, Yamaguchi T, Sawai K and Takahashi T (1996) Overexpression of bax sensitizes human breast cancer mcf-7 cells to radiation-induced apoptosis. Int J Cancer 67: 101-105
22. Sambrook J, Fritsch EF and Maniatis T (1989) Molecular cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N-Y
23. Sherman SE and Lippard SJ (1987) Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 87: 1153-1181
24. Vikhanskaya F, Erba E, D'Incalci M and Broggini M (1994) Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 22: 1012-1017
25. Vikhanskaya F, D'Incalci M and Broggini M (1995) Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int J Cancer 61: 397-401
26. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD and Dorken B (1996) Induction of the death-promoting gene bax-a sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67: 138-141
27. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR and Harris CC (1994) Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding. transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91: 2230-2234
28. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Freidberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeijmakers JHJ, Forrester K and Harris CC (1995) p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 10: 188-195
29. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM and Bates SE (1995) Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Diff 6: 1395-1403
30. Zeng YX and El Deiry WS (1996) Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12: 1557-1564